Navigation Links
Bradmer in Medical News

Notice of Bradmer Pharmaceuticals Conference Call

TSX: BMR TORONTO, March 5 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, will release its year end fiscal results for 2007 on March 12, 2008, at 7:00 AM E...

Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid

...BMR TORONTO, July 17 /PRNewswire-FirstCall/ - bradmer Pharmaceuticals Inc. (TSX: BMR) ("Bradmer" or the ... fees and expenses of the Offer, will be funded by bradmer out of cash on hand. "While we continue to pursu...e existing cash on hand will be utilized to ensure bradmer is left with no future obligations or liabilities....

Bradmer announces 2009 first quarter operational and financial results

...: BMR TORONTO, May 7 /PRNewswire-FirstCall/ - bradmer Pharmaceuticals Inc. ("Bradmer" or the "Company") ...AAP). For the three months ended March 31, 2009, bradmer recorded a net loss of $2,192,000 or $0.16 per com...ntly lower interest rates. As at March 31, 2009, bradmer had available cash of $5,982,000 as compared to ca...

Bradmer announces 2008 fourth quarter and fiscal year operational and financial results

...MR TORONTO, March 31 /PRNewswire-FirstCall/ - bradmer Pharmaceuticals Inc. ("Bradmer" or the "Corporatio...ian GAAP). For the year ended December 31, 2008, bradmer recorded a net loss of $11,529,000 or $0.85 per co...2008, compared to $2,620,000 in 2007. During 2007, bradmer manufactured drug product and conducted considerab...

Bradmer implements cash conservation plan

...MR TORONTO, March 5 /PRNewswire-FirstCall/ - bradmer Pharmaceuticals Inc. (BMR.TSX), today announced th...hile the strategic evaluation process is underway, bradmer has suspended patient enrollment in the GLASS-ART ...ve Officer of Bradmer. "The major cost drivers for bradmer are clinical operations support, patient enrollmen...

Bradmer provides clinical trial update and announces evaluation of strategic alternatives

...BMR TORONTO, Feb. 17 /PRNewswire-FirstCall/ - bradmer Pharmaceuticals Inc. (BMR.TSX), provided an update...most advanced form of brain cancer (glioblastoma). bradmer also announced that its Board of Directors has rec...with regulatory and budgeting processes completed. bradmer has now also completed a review of the first cohor...

Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference

... TORONTO, Dec. 9 /PRNewswire-FirstCall/ - bradmer Pharmaceuticals Inc., a biopharmaceutical company ...n, Ph.D., President and Chief Executive Officer of bradmer will be presenting as a panel participant at the 2...e for 30 days after the conference. About bradmer Pharmaceuticals Inc. ( www.bradmerpharma.com ) ...

Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting

... TORONTO, Nov. 19 /PRNewswire-FirstCall/ - bradmer Pharmaceuticals Inc., a biopharmaceutical company ...but absent from normal brain cells. About bradmer Pharmaceuticals Inc. ( www.bradmerpharma.com ) bradmer Pharmaceuticals is a biopharmaceutical company foc...

Bradmer announces 2008 third quarter operational and financial results

...X: BMR TORONTO, Nov. 10 /PRNewswire-FirstCall/ - bradmer Pharmaceuticals Inc., a clinical oncology company ...arch organizations of $745,000. During the period, bradmer expanded drug manufacturing analytical support and...es over the past year. As at September 30, 2008, bradmer had available cash and cash equivalents and short-...

Bradmer to present at Rodman & Renshaw Healthcare Conference

...SX: BMR TORONTO, Nov. 3 /PRNewswire-FirstCall/ - bradmer Pharmaceuticals Inc., a biopharmaceutical company ... cells but absent from normal brain cells. About bradmer Pharmaceuticals Inc. (http://www.bradmerpharma.com ) bradmer Pharmaceuticals is a biopharmaceutical company foc...
Bradmer in Medical Technology

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

...X: BMR TORONTO, July 17 /PRNewswire-FirstCall/ - bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutic... months in 19 GBM patients treated with Neuradiab. bradmer is currently conducting a Phase III clinical trial...and Drug Administration (FDA) which suggested that bradmer may opt to evaluate sensitivities around the merit...

Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings

... of internal radiation directly to tumor cells." bradmer is preparing to initiate a proposed multicenter Ph...Food and Drug Administration regulatory approvals, bradmer plans to begin its multicenter clinical trial of N... cells but absent from normal brain cells. About bradmer Pharmaceuticals Inc. (
(Date:9/22/2014)... sequencing technologies continue to evolve rapidly, becoming part of ... appropriate policies and regulatory frameworks to address potential challenges, ... issue of the Journal of Law, Medicine & ... with the Center for Medical Ethics and Health Policy ... tools to jumpstart this process. , Experts with ...
Breaking Biology News(10 mins):Federal food program puts food on the table, but dietary quality could be improved 2Reversing the effects of pulmonary fibrosis 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3
Other Contents